224 related articles for article (PubMed ID: 20415226)
21. [Direct renin inhibition: a new and promising treatment principle in heart failure?].
Mahfoud F; Ukena C; Böhm M
Dtsch Med Wochenschr; 2009 Apr; 134(15):759-62. PubMed ID: 19340755
[No Abstract] [Full Text] [Related]
22. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
Ram CV
Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren in the treatment of hypertension and organ damage.
Riccioni G
Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
[TBL] [Abstract][Full Text] [Related]
25. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
26. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
27. Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease.
Kapoor S
Int Urol Nephrol; 2008; 40(4):1115-6. PubMed ID: 18807206
[No Abstract] [Full Text] [Related]
28. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
29. Direct Renin inhibition: promising treatment in renoprotection?
Loriga G
Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):113-9. PubMed ID: 20438446
[TBL] [Abstract][Full Text] [Related]
30. [Contribution of diuretics to the treatment of hypertension in patients with CKD].
Ura N; Yamaji I
Nihon Jinzo Gakkai Shi; 2009; 51(4):446-50. PubMed ID: 19601551
[No Abstract] [Full Text] [Related]
31. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes.
Sakoda M; Ichihara A; Kurauchi-Mito A; Narita T; Kinouchi K; Murohashi-Bokuda K; Saleem MA; Nishiyama A; Suzuki F; Itoh H
Am J Hypertens; 2010 May; 23(5):575-80. PubMed ID: 20075844
[TBL] [Abstract][Full Text] [Related]
32. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
33. Aliskiren: the first direct renin inhibitor for hypertension.
van den Meiracker AH; Jan Danser AH
Curr Cardiol Rep; 2007 Nov; 9(6):470-6. PubMed ID: 17999872
[TBL] [Abstract][Full Text] [Related]
34. Renin inhibition and atherosclerosis.
Luft FC
Nephrol Dial Transplant; 2008 Aug; 23(8):2474-6. PubMed ID: 18430802
[No Abstract] [Full Text] [Related]
35. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
36. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
Tempelhof MW
South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
[No Abstract] [Full Text] [Related]
37. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
38. Aliskiren and dual therapy in type 2 diabetes mellitus.
Ingelfinger JR
N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
[No Abstract] [Full Text] [Related]
39. [spACE, the last frontier? Renin inhibition in hypertension].
Villa L
G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
[No Abstract] [Full Text] [Related]
40. The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases.
Fraga-Silva RA; Da Silva DG; Montecucco F; Mach F; Stergiopulos N; da Silva RF; Santos RA
Thromb Haemost; 2012 Dec; 108(6):1089-96. PubMed ID: 23093373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
